Idera Pharmaceuticals
€0.000000
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
People Also Follow
This list is based on the watchlists of people on Stock Events who follow HXXB.MU. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
Show more...
CEO
Vincent Milano
Employees
13
Country
United States
ISIN
US45168K4058
Listings
0 Comments
Share your thoughts
FAQ
What is Idera Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Idera Pharmaceuticals stocks are traded under the ticker HXXB.MU.
How many employees does Idera Pharmaceuticals have?▼
As of July 08, 2026, the company has 13 employees.
In which sector is Idera Pharmaceuticals located?▼
Idera Pharmaceuticals operates in the Manufacturing sector.
When did Idera Pharmaceuticals complete a stock split?▼
Idera Pharmaceuticals has not had any recent stock splits.
Where is Idera Pharmaceuticals headquartered?▼
Idera Pharmaceuticals is headquartered in Exton, United States.